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ABSTRACT 
Title 
Role of serum ADAMTS13 and von Willebrand Factor (VWF) as early prognostic markers in 
identifying the disease course in Dengue fever.  
Department: Department of Paediatrics, Christian Medical College, Vellore 
Name of the candidate:  Sivamurukan P 
Degree and Subject:  MD Paediatrics 
Word count:  472 
Background 
Dengue is one of the common illnesses affecting children at Vellore and all over India.  A 
significant proportion of children with dengue fever develop severe dengue including 
dengue hemorrhagic fever and dengue shock syndrome.  Although most cases of severe 
illness are characterized by plasma leakage, thrombocytopenia and bleeding, the exact 
pathophysiology is not yet known. There are various proposed theories for causation of 
severe dengue. The recent evidence shown that in dengue patients there is an acquired 
deficiency of ADAMTS13 which causes high levels of VWF and subsequently 
consumptive coagulopathy. 
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This prospective study aims to identify those patients with dengue fever who will 
progress to severe disease by studying whether levels of two important biomarkers of 
endothelial cell activation/ dysfunction, viz. VWF and ADAMTS 13 during early illness 
are predictive of progression to severe dengue and consequent morbidity and mortality.  
Objectives 
To ascertain the role of ADAMTS13 deficiency and von Willebrand Factor (VWF) 
excess as early markers in identification of risk of progression to severe dengue in 
patients with Dengue fever 
Methods  
Prospective study correlating levels of ADAMTS13 and VWF among children with 
dengue during the early febrile phase (day 1-4) with clinical severity and laboratory 
parameters of severe disease.  
Results   
ADAMTS13 levels were deficient in 96% of study children, irrespective of stage or 
phase of dengue infection. Von Willebrand Factor (VWF) activity by collagen-binding 
assay (CBA) was elevated in 89% of children with dengue infection. VWF activity was 
elevated in severe dengue compared to non-severe dengue, and in the early toxic phase 
compared to the febrile phase in children with severe dengue. Neither ADAMTS13 nor 
VWF activity levels were predictive of the WHO clinical stage of severity of dengue 
infection in our children. 
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Among clinical markers of severity of illness, hepatomegaly, ascites and pleural effusion, 
bleeding manifestations, need for blood and inotropic support and total duration of 
hospital stay were all significantly higher in children with severe dengue. 
Hepatomegaly at admission and need for ICU admission were seen in children with 
higher median VWF levels. Need for blood support was significantly associated with 
lower ADAMTS13 levels. 
Conclusions 
Markers of endothelial injury such as low ADAMTS13 activity and elevated VWF 
activity are present in all stages and phases of infection in children with dengue.  The 
median levels of ADAMTS13 and VWF activity did not correlate with either the WHO 
stages of the disease or the phases of the illness, and therefore cannot be used as 
prognostic biomarkers of severity of illness due to dengue. 
 
Key words: ADAMTS13, VWF, DENGUE 
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INTRODUCTION 
 
Dengue fever is also called breakbone fever (1) or dandy fever.  Dengue fever is one of 
the most important mosquito-borne viral diseases in terms of mortality and morbidity 
with a world-wide distribution. Global incidence of dengue has increased over the last 
few decades and severe dengue cases have also increased.  The WHO has estimated that 
there are at least 50 million cases of dengue infection annually, with 5,00,000 cases of 
severe dengue (DHF/DSS) and over 20,000 dengue related deaths (2).  
 
A more recent study from the University of Oxford using a formal modelling framework 
to map the global distribution of dengue risk estimated that the annual incidence of 
dengue could be as high as 390 million, with India contributing the largest number of 
dengue cases with 33 million annual apparent infections(3). 
 
Dengue is one of the common illnesses affecting children at Vellore and all over India.  A 
significant proportion of children with dengue fever develop severe dengue including 
dengue hemorrhagic fever and dengue shock syndrome.   
 
Fatality in dengue fever (DF) ranges from 0.5% to 5% and is seen in the most severe 
forms of dengue fever such as dengue hemorrhagic fever (DHF) or dengue shock 
syndrome (DSS), mainly due to bleeding.  Although severe haemorrhage remains the 
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major cause of death in DHF, the pathogenesis of bleeding is poorly understood, although 
capillary leakage, thrombocytopenia and DIC may be partial explanations of the 
pathogenesis of hemorrhage in DHF. 
 
There is evidence that the haemostatic defect in DHF may be due to the direct effects of 
virus on endothelial cells, or through the activation of immune and inflammatory 
pathways. Recently a few studies have shown that there is an acquired deficiency of 
ADAMTS13, a protease secreted by the endothelial cell, which causes elevated levels of 
Von Willebrand Factor (VWF) resulting in consumptive coagulopathy secondary to 
endothelial activation in severe form of dengue (4–7). 
 
 Here in this study we intend to look whether the levels of ADAMTS 13 and VWF, the 
biomarkers of endothelial activation, are predictive of progression to severe dengue and 
consequent morbidity and mortality. 
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AIMS AND OBJECTIVES 
 
Primary Objective:   
To ascertain the role of ADAMTS13 deficiency and von Willebrand Factor (VWF) excess as 
early markers in identification of risk of progression to severe dengue in patients with Dengue 
fever.  
 
Secondary Objectives:    
1. Clinical: To see whether ADAMTS13 and VWF levels in children in the early 
febrile phase of dengue fever correlate with total duration of hospitalization, 
presence of pleural effusion / ascites, hepatomegaly, bleeding manifestations, 
incidence of shock, need for transfusions, inotropic support and final outcome. 
 
2. Laboratory:  To see whether ADAMTS13 and VWF levels in children in the early 
febrile phase of dengue fever correlate with Haemoglobin, platelets, Prothrombin 
time (PT) and Partial Thromboplastin Time (PTT) at admission and during the 
course of the illness.  
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REVIEW OF LITERATURE 
 
HISTORY  
The word dengue was derived from the Spanish language which means “careful”. This 
depicts the careful gait of a person suffering from bone pain in dengue.  The first case of 
probable dengue fever was reported in Chinese medical encyclopedia as early as (265 – 
420 AD) from the Jin Dynasty which referred to a “water poison” associated with flying 
insects (8) . 
In the 20
th
 century two scientists named Ren Kimura and Susumu Hotta isolated the 
dengue virus in the year 1943 during dengue epidemic in Nagasaki, Japan, in the midst of 
World War II. Later these scientist along with Albert B. Sabin and Walter Schlesinger 
isolated DEN-1(9). Subsequently three other serotypes of dengue virues were isolated. 
 
EPIDEMIOLOGY  
Dengue viruses are single stranded RNA viruses that belong to the genus Flavivirus and 
family Flaviviridae. These viruses are transmitted by mosquitoes to human beings. There 
are four types of dengue viruses namely DEN1, DEN2, DEN3 and DEN4. Dengue fever 
is caused by any of these four closely related dengue viruses 1 to 4.  Infection with one 
serotype does not protect against infection with another serotype, rather it can predispose 
to a more severe form of dengue infection following infection by the second serotype. 
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Dengue fever is currently considered as the most important mosquito-borne viral disease 
with the global incidence of dengue infections increasing rapidly over the last decade. 
The incidence has increased 30-fold over the last five decades as per cases reported each 
year to the World Health Organization  WHO (10).  
 
In 2010, there were 96 million dengue infections globally with Asia contributing to 70 % 
of the disease burden. The table below shows the estimated burden of dengue in 2010, by 
continent (3). 
Estimated burden of dengue in 2010, by continent (3) 
 
 Apparent Inapparent 
 Millions (credible interval) Millions (credible interval) 
Africa 15.7 (10.5 - 22.5) 48.4 (34.3 - 65.2) 
Asia 66.8 (47.0 – 94.4) 204.4 (151.8 – 273.0) 
Americas 13.3 (9.5 - 18.5) 40.5 (30.5 - 53.3) 
Oceania 0.18 (0.11 - 0.28) 0.55 (0.35 - 0.82) 
Global  96 (67.1 - 135.6)  293.9 (217.0 – 392.3) 
 
In India, the first epidemic of dengue-like illness was reported in 1780 in Chennai and 
later between 1963 - 1964 the first virologically proved epidemic of dengue fever (DF) 
was reported in Kolkata (11).  From 2009, India‟s National Vector Borne Disease Control 
Programme has documented over 15,000 cases each year in the country, with the highest 
number of cases so far being 75,808 cases recorded in 2013.     
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The figure below show the distribution of global dengue risk areas based on combined 
reports from WHO and CDC (10).  As shown in the picture below our country lies in 
high suitable area for dengue transmission. 
 
Dengue map (CDC)  
 
STRUCTURE OF DENGUE VIRUS  
The dengue viruses are single-stranded RNA viruses which belong to genus Flavivirus 
and family Flaviviridae. These viruses are transmitted by mosquitoes to human beings. 
There are four types of dengue viruses namely DEN1, DEN2, DEN3 and DEN4. Dengue 
fever is caused by any of these four closely related dengue viruses 1-4.   
Dengue virus is roughly spherical, with a diameter of 50 nm as depicted below in figure.  
The virus has a central core called nucleocapsid which is made of viral genome and C 
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protein. This nucleocapsid is covered by an lipid bilayered envelope with protein 
embedded on it namely protein E and M. These proteins protect the virus from human 
cells.  
The dengue virus genome encodes three structural  proteins (capsid [C], membrane [M], 
and envelope [E]) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, 
NS4B, and NS5) proteins. The function of non structural proteins is replication and 
assembly(12) 
 
ENTOMOLOGY & ECOLOGY 
Dengue virus is transmitted primarily by Aedes group of mosquitoes, namely Aedes 
aegypti, A. albopictus, A. polynesiensis, and A. scutellaris (13). Of these mosquitoes 
Aedes aegypti is the most common one to spread the dengue virus. These mosquitoes live 
in between the latitudes of 35°N and 35°S below an elevation of 1000 m (3300 feet). 
They are called as day biters as the typically bite during early morning and in the 
evening. These mosquitoes live indoors and also rest in cool shaded areas. The male 
mosquitoes do not take blood meal they only feed fruits, whereas the female mosquitoes 
feed both fruits and blood. Aedes aegypti is adapted to breed in and around human 
dwellings and they lay its eggs in clean water. These eggs become an adult mosquito in 
about one-and-a-half to two weeks.  
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This Aedes aegypti mosquito is a small, dark mosquito measuring about 4 to 7 
millimeters in size with typical white markings on the legs and a marking of the form of a 
lyre on the thorax.  Females are larger in size when compared with  males (14).  After a 
blood meal by the female mosquito for an infected person, the mosquito becomes 
infected after about 8 -10 days. It becomes infected for its life time as there is no 
detrimental effects to the mosquito by dengue virus (15). The two phases are aquatic 
phase (larvae, pupae) and a terrestrial phase (eggs, adults).   
 Eggs of these mosquitoes can withstand desiccation for several months. Even if the other 
forms namely larve, pupae and mosquito are eradicated repopulation can occur from 
these eggs once they come in contact with water. Unfortunately, we don‟t have any 
effective way to control these eggs in containers. 
 
DENGUE VIRUS REPLICATION 
Once the human is infected with with dengue virus following a blood meal from a 
mosquito the virus enters the human cell by endocytosis. Following this acidification of  
endosome occurs which lead to release of viral nucleocapsid into the cytoplasm and 
subsequently uncoating of viral genome. This is followed by production of multiple 
copies of viral RNA through process of transcription, translation and replication. This is 
followed by assembly of protein capsid or core (C), premembrane (prM), and envelope 
(E) proteins, along with vRNA into progeny virions, which are transported through the 
Golgi compartment and secreted. 
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COURSE OF DENGUE INFECTION 
 
The incubation period for dengue infection is about 5.9 days, with 95% expected between 
days 3 and 10 (16). Most infection in the pediatric population remains aymptomatic. This 
was demonstrated from Thailand study where about 53%  of dengue infection were not 
associated with symptoms (17). 
The symptomatic group of patients can have mild form or moderate to severe form of 
disease. The moderate to severe form of disease has 3 phases of illness as described 
below. 
1. Febrile phase  
2. Critical phase  
3. Recovery Phase  
 
Febrile phase: 
This phase of illness is characterized by presence of high grade fever which usually lasts 
for 2 – 7 days. During this phase children present with flushing, myalgia, body ache, joint 
pain and head ache(18). Some patients have a biphasic pattern of fever known as 
“saddleback” fever. This second fever phase lasts usually not more than 2 days, this is 
seen in a small proportion of patient with dengue fever.  
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Critical phase: 
A proportion of patient following the febrile phase enter into the critical phase, whereas 
in certain patients the illness resolves as a simple viral infection. With the onset of 
defervescence the symptoms of plasma leakage begin as appearance of warning signs. 
These are abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, 
mucosal bleed, lethargy; restlessness, liver enlargement >2cm. This phase is also 
characterized by a rapid and progressive decrease in platelet count associated with rising 
haematocrit as an early sign of plasma leakage. Leukopenia is usually seen along with 
thrombocytopenia, and it was seen in 76% of patient in a study done in China(19). 
Recovery phase: 
After about  24 – 48 hours of critical phase survival, onset of recovery phase starts which 
is characterized by reabsorption of extravascular fluid into intravascular compartment 
which last for about 48 -72 hours. The patient feels generalized wellness, improvement in 
GI symptoms, increase in urine output and hemodynamic stability occurs. A few patient 
have severe pruritus during the recovery phase. Few patient develop skin rash which is 
classically described as „white islands in a sea of red‟(20). 
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CASE DEFINITION BY WHO 
 The WHO has given the case definition for dengue. In the table below,  we show the 
comparison of old and new case definition between 1997 and 2012 (21). The earlier 
definitions of Dengue Hemorrhagic fever (DHF) and Dengue Shock Syndrome (DSS) 
have been replaced by the terms Dengue with Warning Signs and Severe Dengue, 
respectively.   
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Dengue case definition comparison  
WHO Case Definition 1997 WHO Case Definition 2012 
DF Fever and at least two 
features:  
ocular pain 
headache 
muscle or joint pains, 
cutaneous rash 
bleeding manifestations  
reduced leukocyte count. 
Dengue 
without 
warning 
signs  
Fever and two of the following: 
Nausea, vomiting 
Rash 
Aches and pains 
Leukopenia 
Positive tourniquet test 
DHF Fever lasting from 2-7 
days 
Evidence of hemorrhagic 
manifestation or a 
positive tourniquet test  
Thrombocytopenia 
(≤100,000 cells per mm3)  
Evidence of plasma 
leakage shown by 
hemoconcentration (an 
increase in hematocrit 
≥20% above average for 
age or a decrease in 
hematocrit ≥20% of 
baseline following fluid 
replacement therapy), or 
pleural effusion, or ascites 
or hypoproteinemia. 
Dengue 
with 
warning 
signs 
Dengue as defined above with any of 
the following: 
Abdominal pain or tenderness 
Persistent vomiting 
Clinical fluid accumulation (ascites, 
pleural effusion) 
Mucosal bleeding 
Lethargy, restlessness 
Liver enlargement >2 cm 
Laboratory: increase in HCT 
concurrent with rapid decrease in 
platelet count 
DSS Rapid and weak pulse and 
narrow pulse pressure 
(<20mm Hg), or 
Age-specific hypotension 
and cold, clammy skin 
and restlessness. 
 
Severe 
dengue  
Dengue with at least one of the 
following criteria: 
Severe Plasma Leakage leading to: 
– Shock (DSS)  
– Fluid accumulation with respiratory 
distress 
Severe Bleeding as evaluated by 
clinician 
Severe organ involvement 
– Liver: AST or ALT ≥ 1000 
– CNS: impaired consciousness 
– Failure of heart and other organs 
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DIAGNOSIS  
 
The diagnosis of dengue infection is mainly by clinical assessment. Laboratory diagnosis 
is mainly for confirmation of dengue infection, epidemiological surveillance and 
identification of primary or secondary infection. In many developing countries, including 
India, laboratory confirmation tests are not available throughout the country.  
In order to know the implications of various diagnostic tests for dengue infection, we 
should know the relation of virological and serological marker within the time frame of 
the dengue illness (22). During the early phase of illness confirmatory tests such as virus 
isolation and NS1 antigen detection are useful and during the later phase serological test 
like IgM and IgG can be used as a useful tool for confirmation. 
Thus diagnostic tests can be broadly classified into two groups, namely viral detection 
and serological evidence. The table below clearly show the timing of sample, appropriate 
test and the turnaround time (18). 
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Dengue diagnostic tests 
Tests  Timing of 
sample  
Diagnostic 
method 
Methodology  Turnaround 
time 
Viral 
detection  
Day 1 – 5 of 
illness  
Viral isolation  Culture  One week or 
more 
Nucleic acid 
detection  
RT PCR 1 or 2 days  
Antigen 
detection  
NS1Ag rapid test  Minutes  
NS1Ag ELISA 1 day  
Immuno 
histochemistry 
2- 5  days  
Serological 
evidence 
Paired sample  
Day 1 -5 
followed by 
day 15 -21 days  
IgM or IgG  
seroconversion 
ELISA 
HIA 
1 -2 days   
Neutralization test  Minimum 7 days   
After 5 days  IgM detection  ELISA 1 or 2 days  
Rapid test  Minutes 
IgG detection  IgG ELISA 
HIA 
1 or 2 days 
 
 
 
Interpretation of various tests 
 
The sensitivity of each test varies at each day post-onset of illness. The antigen rapid test 
has greater sensitivity early in the course of infection whereas the IgM and IgG test has 
greater sensitivity later in the course of the infection.  
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NS1Antigen has a peak sensitivity of 75% at days 2 and 3, followed by decrease in 
sensitivity from day 3 onwards. From day 6 the IgM/IgG rapid test shows >95% 
sensitivity (23). 
 
DENGUE PATHOPHYSIOLOGY 
 
The pathogenesis of Dengue fever is not fully understood till now despite extensive 
studies carried out in the last few decades. This is mainly due to the absence of an 
appropriate animal model.  The following table gives the various proposed  mechanisms 
of dengue pathogenesis (24). 
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Various mechanisms proposed for immunopathogenesis of DHF 
Group Mechanism Effects 
Antibody Enhancement of infection Increased cellular infection 
and viral load 
Immune complex Complement activation 
Cross-reactivity with 
endothelial cell and 
coagulation proteins 
Bleeding 
Cross-reactivity with 
endothelial cell and NS1 
protein 
Apoptosis, inflammatory 
activation 
T lymphocytes Suppressor T cells Prevention of DHF, 
increased pathology 
Memory T cell Increased pathology 
Shift from Th1 to Th2 Increased pathology 
Cytokine Tsunami Increased capillary 
permeability 
Bystander cell lysis Liver injury 
Macrophage and 
dendritic cells 
Cytokine tsunami Increased capillary 
permeability 
Free radicals: NO, O2
–
, etc. Increased capillary 
permeability 
Metalloprotein Increased capillary 
permeability 
Vascular endothelial 
cells (mainly in vitro) 
eNOS, NO Increased capillary 
permeability 
Endothelin etc. Increased capillary 
permeability 
IL-8, IL-6 Increased capillary 
permeability 
Decreased soluble vascular 
endothelial growth receptor 2 
Increased capillary 
permeability 
Virus virulence Asian genotype Increased transmissibility 
and cellular infection. 
Selection of virulent strains 
in humans and mosquitoes. 
American genotype Do not produce DHF/DSS 
Host genetics Polymorphism of genes Increased or decreased 
predisposition for DHF 
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Primary infection with any one serotype of dengue virus provides lifelong immunity 
against that serotype, but only partial and transient protection against the other serotypes. 
Secondary infection with a heterologous serotype causes a more severe forms of dengue 
infection, probably attributed  to antibody-dependent enhancement (ADE) of infection 
(25). 
Antibody-dependent enhancement (ADE) is the one of the most common accepted 
hypothesis for dengue pathophysiology (26).  ADE is a phenomenon which involves 
infectious IgG antibody immune complexes whichare responsible for enhancement of the 
disease process. The preexisting heterologous dengue antibody recognizes the infecting 
dengue virus and forms an antigen-antibody complex, which is then bound and 
internalized by immunoglobulin Fc receptors on the cell membrane of leukocytes, 
especially macrophages.  Because the antibody is heterologous, the virus is not 
neutralized and is free to replicate inside the macrophage. Thus, it is hypothesized that a 
prior infection with any serotype, through this process known as antibody-dependent 
enhancement (ADE), enhances the current infection and replication of dengue virus in 
cells of the mononuclear cell lineage (27). Thus resulting in large infected cell mass 
which produces various mediators that promote capillary permeability (28). 
The other important mechanism is cytokine storm. This is because of an aberrant immune 
response which results in production of numerous cytokines which is called the cytokine 
storm. This process is defined as an imbalance between pro-inflammatory cytokines 
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driving an inflammation and anti-inflammatory cytokines suppressing an inflammation.  
There is evidence that viral genotype and host genetic background are key factors driving 
the production of a cytokine storm. Several cytokines are known to cause apoptosis and 
affect adherens junctions in vitro which are thought to the severe form of disease via 
hemorrhage and plasma leakage (29). However there is no evidence whether these 
cytokines may have such effects in vivo. 
 
 
THE ROLE OF SERUM ADAMTS13 AND VON WILLEBRAND FACTOR IN 
THE PATHOGENESIS OF HEMORRHAGE AND COAGULOPATHY IN 
SEVERE DENGUE                           
 
Although severe haemorrhage remains the major cause of death in DHF, the pathogenesis 
of bleeding is poorly understood. Although capillary leakage, thrombocytopenia and DIC 
may be partial explanations of the pathogenesis of hemorrhage in DHF, there is evidence 
that the haemostatic defect in DHF may be due to the direct effects of virus on 
endothelial cells, or through the activation of immune and inflammatory pathways. 
Platelet aggregation to endothelial cells targeted by dengue virus, platelet immune 
destruction by dengue antibody complexes, and thrombotic microangiopathy (TMA) have 
all been described with dengue infection (6). 
TMA in dengue appears to be due to thrombotic thrombocytopenic purpura (TTP) which 
is the result of an acquired deficiency in the ADAMTS13 metalloprotease activity, an 
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enzyme that cleaves newly released large multimers of von Willebrand factor (VWF) 
from endothelial cells and platelets (5). 
 
Endothelial cells have a key role in maintaining blood flow and preventing coagulation in 
the absence of vascular injury. Quiescent endothelial cells generate activated protein C on 
the cell surface, produce tissue plasminogen activator (TPA) to stimulate fibrinolysis, and 
inhibit thrombin formation and platelet adhesion. In the presence of certain activating 
stimuli, the endothelial cell becomes pro-coagulant and secretion of anticoagulant factors 
is reduced. Since infectious pathogens are catalysts for endothelial activation, levels of 
endothelium-derived components of the coagulation pathway have been investigated as 
diagnostic or prognostic markers of endothelial activation or dysfunction in infectious 
diseases(6).  
 
Von Willebrand Factor in Dengue and other infections 
Two studies on sepsis reported that VWF was elevated in patients with sepsis compared 
to healthy adults and non-hospitalized patients (30,31). Another study on mechanically 
ventilated ICU patients found that VWF levels on the day of admission predicted 
mortality in these patients (32). Elevated levels of VWF have been reported in malaria in 
adults and children compared to non-malarial illness and found to be higher in severe 
malaria and cerebral malaria (33,34). VWF has also been explored in a single study as a 
biomarker in dengue virus infection. In Indonesian children with dengue (43 with dengue 
hemorrhagic fever [grade I and II] and 30 with dengue shock syndrome [grade III and 
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IV]), VWF was not consistently correlated with disease severity. The median plasma 
concentration of VWF at enrollment was highest in children with dengue hemorrhagic 
fever (DHF), followed by those with dengue shock syndrome (DSS). However, both 
groups demonstrated median plasma VWF levels higher than those found in uninfected 
children. The presence of significant overlap between VWF levels in individual patients 
in all three groups means that VWF may not be useful as a sole diagnostic marker to 
differentiate DHF from DSS. VWF levels at enrollment did not predict eventual mortality 
even in the most severely ill children (7).  
 
ADAMTS13 in Dengue and other infections  
Normally ADAMTS13, a plasma protease present in plasma regulates  thrombogenicity 
by cleaving the large VWF secreted  in response to injury or stress (35).  This VWF is 
synthesized by the endothelium and stored within Weibel-Palade bodies. VWF are 
secreted as large multimers of various sizes. Following endothelial injury or stress a 
domain on VWF unfolds which allows ADAMTS13 to cleave it into small molecules as 
shown in the figure below. This process is important to maintain homeostasis, because 
the large VWF causes accumulation of platelets  in microvasculature  leading to 
consumption coagulopathy (36). 
 
ADAMTS13 deficiency prevents the cleavage of Large VWF multimers secreted by 
endothelial cells. Platelets carried by flowing blood adhere to the uncleaved VWF 
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multimers, resulting in the development of platelet thrombi and subsequently thrombotic 
microangiopathy. 
 
In a study of 58 children with severe meningococcal septicemia, decreased levels of 
ADAMTS13 were observed. Levels were also lower in non-survivors as compared with 
survivors (37). In another study by Martin et al., median ADAMTS13 levels were highest 
in healthy adults, reduced in adults with organ failure due to non-infectious causes, and 
lowest in those with severe sepsis, in whom ADAMTS13 deficiency was associated with 
mortality. As expected, an inverse correlation with plasma VWF levels was found, with 
the highest VWF concentrations occurring in patients with severe sepsis. However, 
marked overlap in ADAMTS13 values was present between individual patients in all 
three groups (38). 
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ADAMTS 13 activity and VWF cleavage 
 
 
 
ADAMTS 13 defect 
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A single case report of a 45 year old man with severe dengue and thrombotic 
microangiopathy has documented the presence of an ADAMTS13 inhibitor (IgG 
antibody to ADAMTS13) to account for the reason for decreased levels of ADAMTS13 
in dengue (5). In addition, two studies have looked at the correlation of ADAMTS13 
levels with severity of disease in children with dengue.  
 
A study from Thailand comparing 20 children with DF versus 20 children with DHF 
showed significantly decreased levels of ADAMTS13 and elevated levels of VWF in 
children with DHF compared to those with DF as early as 1-4 days of onset of illness (the 
early febrile phase), prior to the toxic phase (between day 5-7) characterized by leakage 
of plasma components into the perivascular space and triggering of the coagulation 
cascade (4). 
 
Another study from Indonesia also demonstrated the same findings in children with DHF 
compared to healthy controls, but did not have a comparator group of children with DF. 
The authors were unable to show that these factors were significantly different in the 6 
children with DHF who died compared to the survivors, owing to their small sample size, 
nor in those with DF as this group was not studied (7). 
 
Peripheral blood biomarkers of endothelial cell activation/ dysfunction may therefore be 
clinically useful to identify those patients with mild forms of potentially life-threatening 
infections such as dengue who will progress to severe disease. A better understanding of 
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these relations might help one to predict the severity of disease progression and thereby 
instigate an early diagnosis and prompt treatment. Moreover, it could help in the 
development of new interventions to supplement the currently recommended fluid 
replacement therapy.  
 
The few studies on biomarkers of underlying endothelial activation/ dysfunction in 
children with dengue may not be uniformly reproducible across patient populations and 
have the inherent disadvantage of overlap between patient groups. The purpose of this 
study is to identify markers that are clinically useful regardless of time of sampling and 
able to identify a subset of patients at high risk for complications or mortality before this 
risk is evident on the basis of classically recognized markers of disease such as bleeding, 
severe thrombocytopenia or DIC. 
 
 
 
 
 
 
 
29 
 
MATERIALS AND METHODS 
 
Type of study  
Prospective cohort study correlating levels of ADAMTS13 and VWF among children 
with dengue during the early febrile phase (day 1-4) with clinical severity and laboratory 
parameters of severe disease.  
Study subjects 
1. Inclusion Criteria 
Children less than 16 years with probable dengue fever (symptoms suggestive of dengue fever 
such as nausea or vomiting, rash, aches or pains, or a positive tourniquet test as per WHO case 
classification 2012) in the febrile phase (day 1-4) and early toxic phase (day 5). 
                     
2. Exclusion criteria 
Children with probable dengue presenting to hospital beyond the early phase (after day 5 of 
onset). 
 
3. Selection of study subjects 
Children with probable dengue were included in the study if they were positive on diagnostic 
testing for dengue infection with Dengue NS1 antigen or serology (Dengue IgM and IgG). 
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Methodology of study 
As this is a prospective study, data was collected in real time as soon as a child presented to 
hospital with suspected dengue fever. The initial consent form was administered at the time of 
admission, after which blood samples were collected. The following parameters were recorded at 
admission: 
1. Detailed clinical status at admission: duration of fever plus 2 criteria for diagnosis of 
probable dengue: nausea / vomiting; rash; aches and pains; positive tourniquet test; 
leucopenia. 
2. Presence of warning signs: Abdominal pain / tenderness; persistent vomiting; ascites / 
pleural effusion; mucosal bleed; lethargy / restlessness; liver > 2 cm; increasing 
hematocrit with concomitant fall in platelets.  
The following clinical parameters were monitored daily for the duration of hospital stay:  
3. Clinical: Temperature, presence of Pleural effusion / ascites / hepatomegaly; bleeding 
manifestations; shock and inotropes / transfusions given;  
4. Lab: hemoglobin, platelets, PT and PTT, ALT. 
5. Outcome was measured and documented.  
6. All children with confirmed dengue infection were tested for ADAMTS13 and VWF 
from blood samples taken and stored at first presentation to hospital.  
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Algorithm of the study 
 
 
 
Variables 
All children with laboratory-confirmed dengue were divided into two groups, dengue 
(including those with warning signs) and severe dengue based on clinical severity of the 
infection as per the WHO criteria given above.  
Final outcome and Classification of severity were recorded for final analysis
Patients were followed up daily till discharge 
VWF and ADAMTS13 levels done in those with positive NS1Ag, Ig M, Ig G
Dengue NS1Ag, IgM and IgG  done to diagnose dengue fever
Daily monitoring  of clinical and laboratory parameters
Treatment as per standard WHO protocol 
Blood samples for VWF and ADAMTS13 collected, along with routine samples  and 
stored
Informed consent taken
Children with probable dengue presenting to Pediatric Casualty / OPD
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.  
The primary outcome variable was the grading of clinical severity in all children with 
laboratory-confirmed infection, with the prognostic predictors of illness being the levels 
of ADAMTS13 and VWF in these children. The levels of these were compared between 
the two groups of interest, viz. Dengue and Severe dengue. 
Secondary outcomes of interest were compared between the 2 groups as follows: 
Clinical: total duration of fever; presence of pleural effusion / ascites, hepatomegaly,  
bleeding manifestations, incidence of shock, need for transfusions, inotropic support and 
duration of such support and final outcome 
Laboratory: Hemoglobin, platelets, PT and PTT, ALT. Duration of thrombocytopenia, 
hemoconcentration and prolonged bleeding parameters.   
 
Data Sources/measurement: 
1. Fluorescence Resonance Energy Transfer [FRET] assays were used to measure 
ADAMTS 13 activity.  In this test proteolytic cleavage of the VWF 86-ALEXA 
FRET substrate by ADAMTS13 uncouples the ALEXA fluorochromes resulting 
in an increase in fluorescence. This increase in fluorescence is measured by a 
spectrofluorometer and the activity of ADAMTS13 in the plasma is determined. 
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2. Collagen Binding Assay (CBA), an ELISA procedure that quantitates the binding 
of VWF to collagen coated onto microtiter wells is used to measure VWF activity. 
Collagen binding of VWF is specifically associated with the higher molecular 
weight (HMW) forms of VWF, than lower molecular weight (LMW) forms. In 
Dengue, there is excess higher molecular weight multimers of Von Willebrand 
factor (VWF) due to secondary ADAMTS 13 deficiency. Therefore CBA may 
correlate more closely with HMW VWF levels which is raised in dengue fever and 
helps in indirect measurement of ADAMTS13 activity. 
 
Sampling details:  
2.7 ml of blood was collected in a Vacutainer (Light blue top) with anticoagulant 
Trisodium citrate with a ratio of anticoagulant to blood 1: 9.  Approximately 5 ml of 
blood collected in a EDTA tube was sent to Virology for  purpose of confirmatory testing 
for dengue including NS1Antigen, Dengue IgM and IgG.  
Minimizing Bias: 
 
ADAMTS 13 and VWF levels were analysed by the clinical pathologist who was blinded 
to the clinical status of the patient. The principal investigator was blinded from the lab 
analysis of the levels of VWF and ADAMTS13 till the time of analysis.  
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Sample size:  
With reference to the article “Activation of endothelial cells, coagulation and fibrinolysis 
in children with Dengue virus infection” by Sosothikul D, Seksarn P, Pongsewalak S, 
Thisyakorn U, Lusher J. published in Thromb Haemost 2007, the required sample size to 
show that ADAM TS13 and VWF to prognosticate the severity of dengue was found to 
be 120 subjects (dengue confirmed subjects) with 80% power and 5% level of 
significance with an anticipated odds of 2 and 10% loss to follow up. 
Sample size calculation 
Regression methods - Multiple  logistic regression 
Proportion of disease  0.44 0.44 0.44 
Anticipated odds ratio 2 2 1.5 
Power (1- beta) % 80 80 80 
Alpha error (%) 5 5 5 
1 or 2 sided 2 2 2 
Multiple correlation coefficient of the exposure variable with the 
confounders  
0.3 0.5 0.3 
Required sample size 104 126 243 
10% Loss to follow-up 116 140  
 
Quantitative variables: 
Since there are no defined normal levels in Indian children for ADAMTS13 or VWF, we 
have used data from an article from Brazil for levels in normal children to derive the 
following cut-offs: 67 to 115 % activity for ADAMTS13 in normal children, 54 to 72% 
activity for VWF in normal children (39). 
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Statistical methods:  
 
1. Frequency and percentage were calculated for categorical data 
2. Mean with Standard Deviation and Median with interquartile range (IQR) were 
calculated for Continuous variables. 
3. ANOVA, Chi-square and Kruskal-Wallis tests were used to calculate significance 
between dengue subgroups for baseline characteristics. 
4. Mann-Whitney test (for 2 groups)  was used to look for significance of median 
ADAMTS13 and VWF levels against Stages and phases of dengue illness, and 
measures of illness documented as categorical variables. 
5. Kruskal-Wallis test (for 3 groups and above) was used to look for significance of 
normal and abnormal ADAMTS13 and VWF levels against stages of dengue illness.   
6. Scatter Plot was done for ADAMTS13 and VWF levels against both clinical and 
laboratory measures of severity of illness recorded as continuous variables.    
7. Each measure of severity of illness was then assessed against ADAMTS13 and VWF 
levels using the Spearman correlation coefficient, to generate r values to look for 
significant correlations. 
 
IRB Approval: 
The study was approved by Institutional Review Board, CMC Vellore on October 27
th
 
2014. 
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RESULTS 
 
 
This study was done from November 2014 to September 2015 and included children 
presenting during two dengue seasons (November 2014 to February 2014 and July 2015 
to September 2015). A total of 183 children had probable dengue, of whom 51 children 
were excluded. Reasons for exclusion included absence of laboratory confirmation of 
disease with negative NS1 antigen and negative Dengue IgM / IgG, or insufficient blood 
samples or clotted samples. 132 patients were eligible for analysis and were enrolled in 
this prospective observational study.  Although 2 patients were lost to follow up, however 
analysis was done in all the 132 patients. Thus the calculated sample size of 120 patients 
with 80% power and 5% level of significance with anticipated odds of 2 and 10% loss to 
follow up was achieved.  
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Figure 1 Study Profile 
 
 
 
 
183 patients with Probable Dengue
132 patients had 
VWF and ADAMTS13 
analysis 
Dengue
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Dengue with 
warning signs n = 
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Severe dengue 
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from VWF and 
ADAMTS13 analysis   
Clotted sample, insufficient 
samples,  and those with no  
laboratory confirmation i.e 
Negative dengue serology 
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Table 1Demographic and baseline characteristics of study subjects 
Baseline 
characteristics 
Total  
 (n=132) 
 Dengue 
(n=6,   
4.5%) 
Dengue with 
warning signs  
(n= 96,   
72.7%) 
Severe 
Dengue  
(n= 30,   
22.7%) 
p value 
Age, in months   
(Mean ± SD) 
70.3   
±  48.5 
46  
± 41.4 
76.8  
±  48.1 
54.3   
± 47.1 
0.022 * 
Age in months n (%)  
0 -60  65 (49.2) 4 (6.3) 42 (64.6) 19 (29.2) 0.283 
61 - 120 43 (32.6) 2 (4.7) 34 (79.1) 7 (16.3) 
121 - 180  24 (18.2) 0 20 (83.3) 4 (16.7) 
Gender males n (%) 63 (47.7) 2 (3.2) 49 (77.8) 12 (19.0) 0.441 
Weight in Kg   
(Mean ± SD) 
19.7 ± 
13.2 
13.7 
± 6.9 
20.6 
± 12.9 
18.2 
± 14.5 
0.110* 
Dengue antigen testing and serology   
Dengue serology 
done, n (%) 
132 (100) 6 (4.5) 96 (72.7) 30 (22.7)  
NS1Ag positive, n 
(%) 
64 (48.5) 4 (6.2) 47 (73.4) 13 (20.3) 0.571 
Immunoglobulin M 
positive, n (%) 
95 (72) 4 (4.2) 68 (71.6) 23 (24.2) 0.789 
Immunoglobulin G 
positive, n (%) 
84 (63.6) 3 (3.6) 60 (71.4) 21 (25.0) 0.588 
Clinical parameters  
Day of illness at 
admission 
 (Mean ± SD) 
4.2 
± 0.7 
3.8 
± 0.4 
4.2 
± 0.8 
4.3 
± 0.6 
0.279** 
Rashes  18 (13.6) 1 (16.6) 13 (13.5) 4 (13.3) 0.975 
Aches and pains 39 (29.5) 0 29 (30.2) 10 (33.3) 0.254 
Abdominal pain  67 (50.8) 1 (16.6) 51 (53.1) 15 (50.0) 0.222 
Persistent Vomiting 15 (11.4) 1 (16.6) 8 (8.3) 6 (20.0) 0.196 
Ascites and pleural 
effusion 
40 (30.3) 1 (16.6) 19 (20.0) 20 (66.6) <0.001 
Hepatomegaly 64 (48.5) 1 (16.6) 41 (43.2) 22 (73.3) 0.004 
Onset of fever 
defervescence (days) 
5.9 
 ±4.2 
5.2 
 ± 0.4 
5.8 
 ±4.7 
6.5  
± 2.5 
0.037* 
Onset of platelet 
recovery (days) 
7.6 ±1.5 5.7 
±0.9 
7.59  
±1.3 
8.12  
±2.0 
0.007* 
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Laboratory parameters   
Hemoglobin at 
admission, g/dl  
(Mean ± SD) 
12.8 
±  1.9 
11.5 
± 0.7 
12.9 
±  1.2 
13.2 
± 2.6 
0.126** 
Platelet Count/cu 
mm at admission 
(Mean ± sd) 
68469  ±  
50799 
154333 
± 73396 
73697.92 
± 46096 
34566.67 
± 31028 
<0.001* 
Platelets 
concomitant with 
ADAMTS13 
 (Mean ± SD) 
62840  ±  
47799 
137666 
± 66863 
66468.75 
± 44306 
36266.67 
± 34455 
<0.001* 
Leukopenia present 41 (31.1) 1 (2.4) 37 (90.2) 3 (7.3) 0.010 
Severity Variables   
Inotropes needed 
 n (%) 
17 (12.9) 0 0 17 (56.6) <0.001 
Bleeding 
manifestations, n 
(%) 
15 (11.4) 0 6 (6.3) 9 (30.0) 0.001 
Transfusions given  
n (%) 
30 (22.7) 0 8 (33.3) 22 (73.3) <0.001 
Oxygen given n (%) 22 (16.7) 0 0 22 (73.3) <0.001 
Hospitalized 
 n (%)    
126 
(95.5) 
3 (50.0) 93 (96.8) 30 
(100.0) 
<0.001 
PICU care, n (%)    9 (7.1) 0 0 9 (30.0) <0.001 
Mortality 
n (%)   
2 (1.5) 0 0 2 (6.6) <0.001 
Duration of stay 
 (Mean ± SD) 
4.67 
±  2.92 
2.67 
±1.15 
3.98 
± 1.38 
7.00 
± 4.82 
<0.001* 
           p value by Chi-square test except for * by Kruskal-Wallis test  & ** p value from ANOVA 
 
 
 
 
 
40 
 
Table 1 shows the demographic and baseline characteristics of the 132 children included 
in the study. They were classified into three categories according to the WHO case 
definition: Dengue, Dengue with warning signs and Severe Dengue. The majority of 
children were in the category of Dengue with warning signs (96; 72.7%), followed by 
Severe Dengue (30; 22.7%) with very few children who had Dengue without warning 
signs (6; 4.5%), as shown in the pie diagram (Figure 2) below. 
 
Figure 2  Classification of dengue subjects as per WHO Case Definition 
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The mean age of study children was 70.3 months, with mean age of children with dengue 
being 46 months, dengue with warning signs being 76.8 months and severe dengue being 
54.3 months. Children were further subcategorized into less than 60 months, 61 to 120 
months and 121 to 181 months.  65 (49.2%) of study children were younger than 60 
months, of whom 4 (6.3%) had dengue, 42 (64.6%) had dengue with warning signs and 
19 had severe dengue.  43 (32.6%) of children were aged between 61 – 120 months; 
among these 2 were dengue, 34 (79.1%) had dengue with warning signs and 7 had severe 
dengue.  24 (18.2%) children were 121 – 180 months of age, with 20 children with 
dengue with warning signs and 4 with severe dengue (Figure 3).  
 
Figure 3 Number of dengue subjects based on age in months and diagnosis 
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Among these 132 children, there was a nearly equal sex distribution with 63 (47.7%) 
being boys and 69 (52.3%) being girls (Figure 4).  
Figure 4 Sex distribution 
 
 
Mean weight of the 132 children was 19.7 kilograms (SD=13.2). Mean weight of 
children with dengue was 13.7 kg, in those with dengue and warning signs was 20.6 kg 
and in those with severe dengue was 18.2 kg.  
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All 132 (100%) children had undergone confirmatory tests for dengue, of whom 64 
(48.5%) were positive by NS1 Antigen, 95 (72%) had positive Dengue IgM serology. 84 
(63.6%) children also had a positive Dengue IgG (Figure 5).  
 
Figure 5  Number of patients with NS1Ag, IgM, IgG Positivity among the groups 
 
 
 
The mean day of illness at admission was 4.2 days with Standard Deviation (SD) of 0.7.  
Mean day of illness at admission did not differ between the subcategories, being 3.8 days 
(+/- 0.4) in children with dengue, 4.2 days (+/- 0.8) in dengue with warning signs and 4.3 
days (+/- 0.6) in children with severe dengue. 
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Clinical parameters at admission except those reflecting severity of illness were 
proportionately divided between the 3 subcategories. Of the 132 patients, 18 (13.6%) had 
rashes at admission, including 16% of children with dengue and 13% of children with 
dengue and warning signs and severe dengue.  39 (29.5%) had aches and pains at 
admission, including one-thirds of those with dengue and warning signs and severe 
dengue. 67 (50.8%) had abdominal pain at admission, including 16% of those with 
dengue and in just over 50% of those with dengue and warning signs, and severe dengue. 
15 (11.4%) had persistent vomiting at admission, including 16%) of  dengue, 8%of those 
with dengue and warning signs and 20%) of  children with severe dengue.   40 (30.3%) 
had signs of plasma leakage with ascites and pleural effusion at admission, including 1 
child with dengue, 20% of those with dengue and warning signs and two-thirds of those 
with severe dengue.  64 (48.5%) had hepatomegaly at admission, including   1 child with 
dengue, 43% of those with dengue and with warning signs and 73%) of those with severe 
dengue. Duration of days taken for fever defervescence and onset of platelet recovery 
was significantly higher with increasing severity of illness, as was total duration of 
hospital stay in children with severe dengue which was nearly double of those with non-
severe dengue.  
Laboratory parameters reflected severity of illness. The mean hemoglobin at admission 
was 12.9 +/- 1.9 gm% among 132 patients, of whom patients with dengue had a mean of 
11.5+/- 0.7 gm%, dengue with warning signs had a mean of 12.9+/- 1.2 gm%, and 
patients with severe dengue had 13.2 +/- 2.6 gm%. The mean platelet count at admission 
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was 68,469/cu. mm. (SD 50,799) among the 132 patients. It was significantly different 
between dengue subgroups, with a mean of 1, 54,333/cu. mm. in those with dengue, 
73,697/cu. mm. in dengue with warning signs and 34,566 in those with severe dengue.  
 
Of the 132 patients, 41 (31.1%) had leucopenia at admission, of which 1 (2.4%) was 
among probable dengue, 37 (90.2%) were among dengue with warning signs and 3(7.3%) 
were among severe dengue.   
 
Indicators of severity of illness significantly corresponded to the clinical classification. 
Of the 132 patients, 17 (12.9%) required inotropic support during hospital stay, all of 
them having severe dengue.  15 (11.4%) had bleeding manifestations, including 6%) of 
those with dengue and warning signs and 30% of those with severe dengue.  30 (22.7%) 
required blood product supports during the hospital stay including one-third of those with  
dengue and warning signs and 73.3% of those with severe dengue. 126 (95.55%) of the 
study population were hospitalized. Only half of the children with dengue were 
hospitalized, compared to 97% of those with warning signs and all 30 (100%) of those 
with severe dengue. Two children with severe dengue died. Comparisons of all these 
severity variables are shown in Figure 6 below. 
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Figure 6  Severity Parameters among study population 
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Table 2. Median ADAMTS13 and VWF levels in Dengue classified as per WHO case 
definition   
 Total 
n= 132 
Dengue  
n =6 
Dengue with 
warning 
signs  
n = 96 
Severe Dengue 
n = 30 
p 
value 
ADAMTS 13 % 
(Median, IQR) 
0 0 0 0 (0-14.28) 0.021 
VWF %  
(Median, IQR) 
156.2 
(104.32 - 
228.38) 
119.5 
(94.1 -
152.35) 
159.25  
(104.32 - 
243.55) 
156.70  
(97.52 - 
211.10) 
0.247 
 
Our primary objective was to compare median ADAMTS 13 and VWF levels in children 
with dengue classified by disease severity (Table 2). Among 132 children with dengue, 
the median value of ADAMTS13 % activity in 109 children was 0.  Since a majority of 
patients had undetectable levels of   ADAMTS13, the statistically significant difference 
in these levels found between severe dengue (median value 0,  interquartile range 0 to 
14.8)  compared to non-severe dengue cannot be commented upon. Median VWF % 
activity levels among the 132 study subjects was 156.2 (IQR=104.32 to 228.38). In 6 
children with dengue without warning signs, median VWF level was 119.5 (IQR = 94.1 
to 152.35), in 96 children with dengue and warning signs median VWF was 159.25 (IQR 
= 104.32 to 243.55) and in 30 with severe dengue the median VWF level was 156.70 
(IQR = 97.52 to 211.10) which was not statistically significant. The fact that the numbers 
in each group were so different may have contributed to this finding. 
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Table 3. Median ADAMTS13 and VWF levels in non-severe and severe Dengue  
 Dengue (Dengue ± warning 
signs) n= 102 
(Median, IQR) 
Severe Dengue 
n= 30 
(Median, IQR)  
p value 
ADAMTS 
13 levels 
(% activity) 
0 0  
(0 - 14.28) 
0.148 
VWF levels 
(% activity) 
154.75 
(104.48 - 225.82) 
164.05 
(97.52 - 211.10) 
0.651 
 
As we had lesser number of children in the Dengue group, we combined Dengue with 
and without warning signs and compared their ADAMTS 13 and VWF levels against 
levels in children with Severe Dengue, (Table 3).  There was no statistically significant 
difference in ADAMTS13 levels between the groups thus classified. Median VWF level 
was 154.75 (IQR =104.48 to 225.82) in Dengue group against a median VWF level of 
164.05 (IQR = 97.54 to 211.10) in Severe Dengue. No statistically significant difference 
was found in VWF levels between the groups. This may be due to the skewed distribution 
of patients, with only a third of our children having severe dengue, while two-thirds had 
non-severe dengue. 
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Table 4. Median VWF and ADAMTS 13 levels in the febrile and toxic phases of 
non-severe and severe Dengue 
 Febrile phase  day 1- 4    
n = 83 (Median, IQR) 
Toxic phase day 5 +  
 n = 49 (Median, IQR) 
 Dengue  Severe 
dengue 
p value Dengue Severe 
dengue 
p value 
ADAMTS 13 
Levels 
(% activity) 
0 0 
(0 - 7.80) 
0.22 0 0  
(0 - 30.80) 
0.414 
VWF levels 
(% activity) 
163.25 
(113.18 -
215.38 ) 
159.70 
(96.70 -
260.20) 
0.822 138.40 
(97.78 - 
258.68) 
168.40 
(68.40 - 
194.90) 
0.666 
 
Median ADAMTS 13 and VWF levels were compared between non-severe and severe 
dengue in the febrile phase (day 1-4) and toxic phase (day 5+) of Dengue, based on day 
of presentation (Table 4). There was no statistically significant difference in ADAMTS13 
and VWF levels between children presenting prior to or after day 5 of illness, in either 
non-severe or severe dengue. 
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Table 5. Normal vs Abnormal ADAMTS13 levels in dengue classified as per WHO 
case definition 
 ADAMTS 13 levels  (Normal 67 – 115 % activity) p value  
 
 
0 
 
 
1 – 66 % 
Normal 
67 - 115 % 
 
 
>115 % 
Dengue  
       n (%) 
 
6 (100.0) 
 
0 
 
0 
 
0 
 
 
 
 
 
 
 
0.047 
Dengue with 
warning signs 
       n (%) 
 
 
83 (86.5) 
 
 
12 (12.5) 
 
 
1 (1.0) 
 
 
0 
Severe dengue 
       n (%) 
 
20 (66.7) 
 
6 (20.0) 
 
3 (10.0) 
 
1 (3.3) 
 
ADAMTS 13 values in our children were categorized as normal, subnormal and elevated 
levels based on historical data for normal values for ADAMTS13. These levels were then 
compared between dengue subgroups as per the WHO case definition (Table 5).  
All 6 children with probable dengue had undetectable ADAMTS13 levels. In dengue 
with warning signs, ADAMTS13 levels were undetectable in 83 (86.5%), subnormal in 
12 (12.5%) and normal in only one child (1%). No child had elevated levels of 
ADAMTS13. In those with Severe dengue, ADAMTS13 was undetectable in 20 (66.7%). 
ADAMTS 13 levels were subnormal in 6 (20%), normal in 3 (10.0%) and one child had 
an elevated level of ADAMTS 13 level >115. There was a statistically significant 
difference in ADAMTS13 between groups, with p value=0.047. 
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Table 6. Normal vs Abnormal ADAMTS13 levels in non-severe and severe dengue 
 
ADAMTS 13 Levels  (Normal 67 – 115 % activity) 
 
0 1 - 66 
Normal 
67 -115 >115 p value  
Dengue  
       n (%) 89 (87.3) 12 (11.8) 1 (1.0) 0 
0.007 
Severe dengue 
       n (%) 20 (66.7) 6 (20.0) 3 (10.0) 1 (3.3) 
 
ADAMTS13 levels were also compared between non-severe dengue (with and without 
warning signs) and severe dengue (Table 6).  
All 6 children with probable dengue had undetectable levels. 89 children with dengue 
(87.3%) had undetectable ADAMTS13 levels. ADAMTS13 values were subnormal in 12 
(11.8%), normal in 21 (18.1%). No child had elevated levels of ADAMTS13. In those 
with Severe dengue, ADAMTS13 was undetectable in 20 (66.7%). ADAMTS 13 levels 
were subnormal in 6 (20%), normal in 3 (10.0%) and only one child had an elevated level 
of ADAMTS 13 level >115. There was a statistically significant difference in 
ADAMTS13 between groups, with p value=0.007. 
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Table 7. Normal vs Abnormal VWF levels in dengue classified as per WHO case 
definition 
 VWF levels  (Normal 54 – 72 % activity)   
 
 
<54 % 
Normal 
54 – 72 % 
 
 
> 72 % 
 
p value  
Dengue 
       n (%) 
 
0 
 
1 (16.7) 
 
5 (83.3) 
 
 
 
 
 
0.373 
Dengue with 
warning signs 
       n (%) 
 
1 (1.0) 
 
7 (7.3) 
 
88 (91.7) 
Severe dengue 
       n (%) 
 
2 (6.7) 
 
3 (10.0) 
 
25 (83.3) 
 
VWF values were also categorized as normal, subnormal and elevated levels based on 
historical data, and then compared between dengue subgroups as per the WHO case 
definition (Table 7).  
5 of the 6 children with dengue had elevated levels of VWF, with only one child having a 
normal. 88 (91.7%) of children with dengue and warning signs had elevated levels of 
VWF, with only 7 (7.3%) with normal levels and one child (1%) having a subnormal 
level. There was no statistically significant association of VWF levels with severity of 
illness as per the WHO classification.  . 
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Table 8. Normal vs Abnormal VWF levels in non-severe and severe dengue 
 
VWF levels  (Normal 54 – 72 % activity) 
 
<54 % 
Normal 
54 – 72 % > 72 % p value  
Dengue 
       n (%)  1 (1.0) 8 (7.8) 93 (91.5) 
0.166 
Severe dengue 
       n (%) 2 (6.7) 3 (10.0) 25 (83.3) 
 
VWF levels were also compared between non-severe dengue (with and without warning 
signs) and severe dengue (Table 8). 
93 (91.5%) of children with dengue group had elevated VWF levels, with 8 (7.8%) 
having normal levels and only one child (1 %) with a low VWF level. 25 (83.3%) with 
severe dengue had elevated VWF levels, with 3 (10%) having normal levels and 2 (6.7%) 
with low VWF levels. There was no statistical association of VWF levels with severity of 
illness. 
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Table 9. Relative risk for subnormal ADAMTS13 between dengue subgroups 
ADAMTS13 
(% activity)  
Severe 
Dengue 
Dengue Relative Risk 
(prevalence 
ratio) 
95 % CI p value 
<67 26 101 
0.2559 
0.1467 , 
0.4464 
<0.001 
>67 4 1 
 
In view of the statistically significant difference in ADAMTS13 levels between dengue 
subgroups, relative risk was calculated for ADAMTS13 levels < 67 (the lower limit of 
normal) between dengue and severe dengue (Table 9).    
ADAMTS13 below 67 was only associated with severe dengue in 25% of cases, being 
more likely to be seen in children with dengue than severe dengue compared to the rest. 
This means that an ADAMTS13 level < 67 was not likely to predict severe dengue over 
non-severe dengue.  
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Table 10. Relative risk for elevated VWF between dengue subgroups 
VWF 
(% activity) 
Severe 
Dengue 
Dengue Relative Risk 
(prevalence 
ratio) 
95 % CI p value 
>72 25 93 
0.5932 
0.2708 , 
1.2998 
0.1919 
<72 5 9 
 
Similarly, in view of the difference in VWF levels between dengue subgroups (although 
not statistically significant), relative risk was calculated for VWF levels >72 (the upper 
limit of normal) between dengue and severe dengue (Table 10).    
VWF above 72 was associated with severe dengue in 60% of cases compared to those 
with non-severe dengue. This finding, however, was not statistically significant.  
 
 
 
 
 
 
 
 
56 
 
Figure7.  Scatter Diagram of ADAMTS13 levels versus VWF levels 
 
We also looked for an inverse correlation between ADAMTS13 and VWF levels. As 
expected, lower ADAMTS13 levels corresponded to higher VWF levels. For each unit % 
increase in VWF level, ADATMS13 levels decreased by 0.143 (r) which is not 
significant (p = 0.102). This lack of significance may be due to the large number of null 
(0) values of ADAMTS 13.  
 
We then looked for any significant association of both ADAMTS13 and VWF levels with 
our secondary outcomes of interest, which were clinical and laboratory measures of 
disease severity. Clinical markers of disease severity recorded as categorical variables 
(Present / Absent) were the following: bleeding manifestations, hepatomegaly, need for 
transfusions or inotropic support, and ICU admission.    
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Table 11. Association of clinical markers of disease severity (categorical variables) 
with ADAMTS13 and VWF levels 
 ADAMTS13 VWF 
 Median / IQR p Median / IQR p 
Bleeding 
manifestations 
    
Present 0 0.7 153.70 (68.40 - 200.70) 0.43 
Absent 0 156.20 (105.40 - 229.90) 
Transfusions     
Needed .00(.00 - 23.65) 0.008 157.50 (88.40 - 248.65) 0.554 
Not needed 0 156.20 (108.90 - 218.62) 
Hepatomegaly     
Present 0 0.5 171.10 (107.22 - 252.55 0.134 
Absent 0 147.70 (101.05 - 198.32) 
Shock     
Present .00(.00 - 3.90) 0.306 159.70 (89.40 - 243.95) 0.559 
Absent 0 156.20 (107.70 - 224.40) 
Inotropes     
Used 0 (0 - 14.60) 0.124 146.60 (67.55-  217.30 ) 0.223 
Not used 0 156.20 (107.70 - 230.10) 
ICU Admission  
 
    
Needed 0 0.254 160.70 (103.98 - 232.52) 0.201 
Not needed 0 131.55 (99.35 - 148.78) 
 
 
Table 11 compares median ADAMTS 13 & VWF levels in children with and without 
clinical markers of disease severity recorded as categorical variables.  Only need for 
transfusions showed a statistically significant association with ADAMTS 13 levels (p = 
0.008). Transfusion requirement was not significantly associated with median VWF 
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level. Hepatomegaly at admission and need for ICU admission corresponded to higher 
mean VWF levels, however this was not statistically significant. None of the other 
categorical markers of disease severity were significantly associated with median 
ADAMTS13 or VWF levels. 
 
 
 
 
We also looked for any correlation of both ADAMTS13 and VWF levels with clinical 
and laboratory measures of disease severity recorded as continuous variables.  Clinical 
measures of disease severity recorded as continuous variables were duration of hospital 
stay in days, days taken for fever defervescence,  numbers of transfusions received, 
number of fresh frozen plasma (FFP and platelet transfusions received), and days taken to 
onset of platelet recovery. As ADAMTS13 and VWF as well as our clinical measures of 
disease severity were ranked continuous variables, we used Spearman‟s rank correlation 
for measure of statistical dependence between two ranked variables.   
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Figure 8. Scatter Diagram for Duration of stay in days against VWF levels 
 
Figure 9. Scatter Diagram for Duration of stay in days against ADAMTS13 levels 
 
The scatter diagrams for duration of stay in days against VWF levels (Figure 8) and 
ADAMTS13 levels (Figure 9) show no increase in duration of stay with increasing VWF 
levels or decreasing ADAMTS13 levels. There was no significant correlation between 
duration of hospital stay and the levels of Von Willebrand Factor (correlation coefficient 
r = 0.044, p value 0.628) or ADAMTS13 (correlation coefficient r = 0.164). 
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Figure 10. Scatter Diagram for Days to Fever defervescence against VWF levels 
 
Figure 11. Scatter Diagram for Days to Fever defervescence against ADAMTS 13 
levels 
 
The scatter diagrams for days to fever defervescence against VWF levels (Figure 10) and 
ADAMTS13 levels (Figure 11) show no increase in days taken for fever to subside with 
increasing VWF levels or decreasing ADAMTS13 levels. There was no significant 
correlation between fever defervescence and the levels of Von Willebrand Factor 
(correlation coefficient r = 0.064) or ADAMTS13 (correlation coefficient r = 0.016). 
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Figure 12. Scatter Diagram for Days to Onset of platelet recovery against VWF 
levels 
 
Figure 13. Scatter Diagram for Days to Onset of platelet recovery against 
ADAMTS13 levels 
 
The scatter diagrams for days to platelet recovery against VWF levels (Figure 12) and 
ADAMTS13 levels (Figure 13) show no increase in days taken for platelets to recover 
with increasing VWF levels or decreasing ADAMTS13 levels. There was no significant 
correlation between onset of platelet recovery and the levels of Von Willebrand Factor 
(correlation coefficient r = 0.047) or ADAMTS13 (correlation coefficient r = 0.112). 
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Table 12. Correlation of clinical measures of disease severity (continuous variables) 
with ADAMTS13 and VWF levels  
Clinical measures of disease 
severity 
ADAMTS13 levels VWF levels 
r r 
Duration of stay in days 0.164 -0.044 
Fever defervescence  -0.016 0.064 
Number of Transfusions 0.072 0.356 
FFP transfusions -0.056 0.11 
Platelet transfusions  -0.086 0.357 
Onset of platelet recovery 0.112 0.047 
 
Table 12 describes the results of Spearman‟s test for correlation between clinical 
measures of disease severity with ADAMTS 13 and Von Willebrand Factor levels. 
Correlation (r) values with minus (-) signs indicate decreases with decreasing levels of 
ADAMTS13 and VWF, while r values without the minus sign indicate increases with 
increasing levels of ADAMTS13 and VWF.  
For example, for every increase in days taken to fever defervescence, ADAMTS 13 
levels decreased by 0.016 and VWF levels increased by 0.064 which was not statistically 
significant. For every unit increase in number of transfusions, ADAMTS 13 levels 
increased by 0.072 and VWF levels increased by 0.356 which was not statistically 
significant. Similarly there was no statistically significant correlation between other 
clinical measures of disease severity including duration of hospital stay, days taken to 
onset of platelet recovery or number of FFP or platelet transfusions given with 
ADAMTS13 or VWF levels. 
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We also looked for any correlation of both ADAMTS13 and VWF levels with laboratory 
measures of disease severity recorded as continuous variables which were as follows: 
values of Hemoglobin and Platelets at admission, concomitant platelets (collected along 
with ADAMTS13 / VWF sample), Prothrombin time (PT), Partial Thromboplastin Time 
(PTT), and SGPT at admission. We used Spearman‟s rank correlation to look for 
dependence between two ranked variables for all the above. 
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Figure 14. Scatter Diagram for Platelet counts concomitant with VWF levels 
 
Figure 15. Scatter Diagram for Platelet counts concomitant with ADAMTS 13 levels 
 
The scatter diagram for Platelet counts concomitant with sampling for ADAMTS13 and 
VWF (Figure 14) shows no decrease in Platelet counts concomitant with  increasing 
VWF levels (correlation coefficient  r = 0.034). However, platelet count showed a 
negative monotonic relationship with ADAMTS13 (Figure 15), with higher platelet 
counts being associated with decreased levels of ADAMTS13 (correlation coefficient r = 
0.212). 
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Figure16. Scatter Diagram for Prothrombin Time (PT) against VWF levels 
 
 
Figure 17. Scatter Diagram for Prothrombin Time (PT) against ADAMTS13 levels 
 
The scatter diagram for Prothrombin time against levels of Von Willebrand Factor 
(Figure 16) shows no prolongation of Prothrombin time with increasing VWF levels 
(correlation coefficient 0.04). However, Prothrombin time showed a positive monotonic 
relationship with ADAMTS13 (Figure 17), with a trend towards more prolonged 
Prothrombin times with increased levels of ADAMTS13 (correlation coefficient r = 
0.25). 
66 
 
Figure18. Scatter Diagram for Partial Thromboplastin Time (PTT) against VWF 
levels 
 
Figure19. Scatter Diagram for Partial Thromboplastin Time (PTT) against 
ADAMTS 13 levels 
 
The scatter diagram for Partial Thromboplastin time against levels of Von Willebrand 
Factor (Figure 18) shows no prolongation of Partial Thromboplastin time with increasing 
VWF levels (correlation coefficient r = 0.082). However, Partial Thromboplastin time 
showed a positive monotonic relationship with ADAMTS13 (Figure 19), with a trend 
towards more prolonged Prothrombin times with increased levels of ADAMTS13 
(correlation coefficient r = 0.261). 
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Figure20. Scatter Diagram for SGPT against VWF levels 
 
Figure21. Scatter Diagram for SGPT against ADAMTS 13 levels 
 
The scatter diagram for SGPT against levels of Von Willebrand Factor (Figure 20) shows 
no elevation of SGPT with increasing VWF levels (correlation coefficient r = 0.047). 
However, SGPT Partial Thromboplastin time showed a positive monotonic relationship 
with ADAMTS13 (Figure 21), with a trend towards higher SGPT values with increased 
levels of ADAMTS13 (correlation coefficient r = 0.185). 
68 
 
 
 
Table 13. Correlation of laboratory measures of disease severity with ADAMTS13 
and VWF 
 ADAMTS13 VWF 
 r r 
Haemoglobin 0.079 0.095 
Platelets -0.193 0.059 
Concomitant platelets  -0.212 0.034 
PT * 0.25 0.04 
PTT ♦ 0.261 -0.082 
SGPT # 0.185 0.047 
* n = 81,  ♦ n = 80,  # n =128 
Table 13 describes the results of Spearman‟s test for correlation between laboratory 
measures of disease severity with ADAMTS 13 and Von Willebrand Factor levels. 
Correlation (r) values with minus (-) signs indicate decreases with decreasing levels of 
ADAMTS13 and VWF, while r values without the minus sign indicate increases with 
increasing levels of ADAMTS13 and VWF.  
For increasing Haemoglobin levels, ADAMTS 13 levels increased by 0.079 and VWF 
levels increased by 0.095 which was not statistically significant.  None of the laboratory 
measures of disease severity showed a significant positive correlation with VWF levels. 
However, Platelet counts showed a downward trend with higher ADAMTS13 levels, 
while PT, PTT and SGPT values had an upward trend with higher ADAMTS13 levels in 
our patients. We would have expected the reverse, with a positive correlation between 
low platelets and low ADAMTS13 levels and a negative correlation between elevated 
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PT, PTT, SGPT and low ADAMTS13 levels. However, the presence of several repeated 
data values of zero (0)  for ADAMTS13, the presence of several outliers for Platelets, PT, 
PTT and SGPT and the poor correlation coefficient (r; highest value 0.261) means that 
there was very poor correlation between the laboratory measures of disease severity and 
levels of ADAMTS13 and VWF.  
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DISCUSSION  
 
We enrolled 132 children who presented to our pediatric casualty and OPD with signs 
and symptoms of dengue as per the 2012 WHO case definition, with dengue infection 
confirmed by positive dengue serology or NS1 Antigen.  
 
Our study population was nearly equally divided by gender. Children younger than 5 
years of age made up nearly half of our study cohort, and were more in number than 
those aged 5-10 years and those over 10 years of age. Those under 5 years of age had a 
disproportionately higher number of children with severe illness, accounting for two-
thirds of those with severe dengue.  
On dividing the study population into subgroups according to the 2012 WHO case 
definition, a majority of our study children had dengue with warning signs followed by 
those with severe dengue, with only a few presenting at the stage of dengue without 
warning signs. Clinical and laboratory parameters at admission and during the illness 
reflected severity of illness in this cohort of children.     
 
ADAMTS13 and VWF levels in these children were tested for comparison with levels in 
normal children, and analyzed for any association of levels with severity of dengue 
infection.    
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ADAMTS 13 activity in our study population  
ADAMTS13 levels were found to be deficient in all stages of dengue infection, with 96% 
of study children having low levels of ADAMTS 13. Rossi et al documented that 
ADAMTS13 activity was < 5% of normal in a 45 year old man with dengue and 
thrombotic microangiopathy(5).   
 
Similarly Djamiatun et al found a marked reduction in ADAMTS 13 level activity in 
children with severe manifestations of dengue.  In this study they followed a cohort of 73 
Indonesian children of whom 40 had dengue hemorrhagic fever (DHF) and 30 had 
dengue shock syndrome (DSS). They found that 46% of children with DHF and 67% of 
children with DSS had an ADAMTS-13 activity level of ≤50%, with severe ADAMTS-
13 deficiency (≤10%) in 2% of children with DHF and 10% of patients with DSS (7). 
Sosothikul et al studied  42 children in Thailand including 20 children with dengue fever 
(DF) and 22 children with dengue hemorrhagic fever (DHF, including DSS. They 
demonstrated a reduction in ADAMTS13 activity as low as 40% of normal in all three 
phases of dengue including the febrile phase (Day 1-4), toxic phase (Day 5-6) and 
convalescent phases (Day 7-10) of the illness in children with DHF. This reduction in 
ADAMTS13 levels was less marked in children with Dengue fever, compared to 
ADAMTS13 levels in 38 normal controls.(4).  
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In our study, ADAMTS13 activity was reduced in a majority of our children in all stages 
of the illness including Dengue, Dengue with warning signs and Severe Dengue.  There 
was a statistically significant difference in ADAMTS13 levels between groups (p= 
0.021). ADAMTS13 activity was also reduced in both phases (febrile phase and early 
toxic phase) of the illness in our children, without a statistically significant difference 
between groups.  
 
Our study noted a very high number of children (82%) with severe ADAMTS13 activity 
and undetectable levels, compared to only 10% of Indonesian children with dengue in the 
study by Djamiatun et al. Very low levels of ADAMTS13 activity of <5% have also been 
documented by Rossi in an adult with dengue, as well as as low as 10% in adults with 
severe malaria by Lowenberg et al (40). While the extremely low levels of ADAMTS13 
in our children may conceivably be due to misclassification of disease stage, the 
significant difference in clinical and laboratory parameters of severity of illness between 
groups leads us to conclude that such misclassification is not present. Although it is 
reasonable to assume that ADAMTS13 levels in dengue in Indian children differ from 
children from other countries, this finding also leads to the conclusion that normal levels 
of ADAMTS13 activity need to be documented in Indian children, to better elucidate the 
nature of ADAMTS13 activity in children with dengue.          
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In the absence of normal ADAMTS13 standards from Indian children, we used data from 
a Brazilian study(39)  to compare ADAMTS13 levels in our children with dengue 
subgrouped by clinical severity. There was a statistically significant difference in 
ADAMTS13 levels between children with dengue grouped according to the 2012 WHO 
case definition ( p = 0.047) as well as between severe and non-severe dengue (dengue 
with and without warning signs; p = 0.007).  
.  
VWF- CBA activity in our study population  
Von Willebrand Factor (VWF) activity by collagen-binding assay (CBA) was elevated in 
all stages of dengue, with 89% of study children having elevated levels of VWF.  The 
study done by Sosothikul et al in in 42 children with dengue in Thailand showed higher 
levels of VWF:CBA and VWF Antigen in those with dengue hemorrhagic fever (DHF) 
compared to those with dengue fever; however only the latter showed a statistically 
significant difference between the two groups(4). Similarly, Djamiatun et al showed that 
in Indonesian children with dengue, VWF antigen and propeptide levels and VWF 
activation factor were higher in DHF and DSS children compared to normal controls, 
indicating a higher amount of circulating VWF, confirming endothelial injury in dengue. 
They too were unable to show a significant difference between any of the VWF-related 
variables between DHF and DSS (7). 
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In our study as well, VWF: CBA activity that is more specific for large VWF multimers 
was documented in all dengue subgroups in children with dengue, indicating the presence 
of endothelial injury in dengue. There was no statistically significant difference between 
groups. VWF activity was elevated in the early toxic phase (day 5 +) compared to the 
febrile phase (days 1-4) of severe dengue in our children. This difference was, however, 
not statistically significant.    
  
ADAMTS13 and VWF levels as prognostic markers of severity 
In view of the statistically significant difference in ADAMTS13 levels and the difference 
in VWF levels between dengue subgroups, relative risk for ADAMTS13 levels < 67 and 
VWF levels >72 between dengue and severe dengue were calculated for our children.  
 
ADAMTS 13 levels below 67 were more likely to be seen in children with non-severe 
dengue compared to severe dengue, whereas VWF levels above 72 were more likely to 
be seen in those with severe dengue compared to those with non-severe dengue, without 
statistical significance. The skewed distribution of our study population, with only 23% 
of children having severe dengue, may have led to our inability to find a higher risk of 
decreased ADAMTS13 with severe dengue. A study on 94 children from Thailand with 
dengue (21 with DF, 63 with DHF and 10 with DSS) by Chuansumrit et al found 
significantly higher levels of VWF antigen or VWF ristocetin cofactor activity in children 
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with DSS during the first 3 days of illness. They also found that a level of VWF:Ag or 
VWF:Rcof > 210 in the febrile phase conferred a 10.9 higher relative risk of progression 
from DHF to DSS (41). VWF: CBA activity was not assessed in those children. No 
similar data for ADAMTS13 activity was found in other studies on dengue in children.    
      
Lower ADAMTS13 levels corresponded with higher VWF levels in our children, similar 
to other published studies in dengue(7) as well as other conditions associated with 
endothelial injury such as malaria (40) and sepsis-induced organ failure(38). This trend, 
however, was not statistically significant, probably due to the high number of null values 
of ADAMTS13.  
 
The presence of low ADAMTS13 levels and elevated VWF activity in all stages of 
dengue in our study cohort population, while confirming the presence of endothelial 
injury in dengue, leads us to conclude that ADAMTS13 and VWF activity levels cannot 
be used to prognosticate severity of illness according to the subgroups of dengue as per 
the WHO classification. 
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ADAMTS13 and VWF levels against measures of disease severity 
Clinical and laboratory measures of disease severity were also recorded in our cohort of 
children. Hepatomegaly, ascites and pleural effusion, bleeding manifestations, need for 
blood product and inotropic support and total duration of hospital stay were all 
significantly higher in children with severe dengue. These parameters were then 
compared with median ADAMTS13 and VWF levels to look for any association of 
median levels with disease severity. Although hepatomegaly at admission and need for 
ICU admission were seen in children with higher median VWF levels, this association 
was not statistically significant. Need for blood support was significantly associated with 
lower ADAMTS13 levels. Duration of hospital stay, days till fever defervescence or 
platelet recovery, presence of bleeding manifestations, need for inotropic support and 
number of transfusions received did not correlate with median ADAMTS13 or VWF 
levels. Similarly, platelet counts both at admission and when repeated along with 
ADAMTS13 & VWF sampling were significantly lower in children with severe dengue 
compared to the rest. However platelet counts, hemoglobin, prothrombin time, partial 
thromboplastin time and SGPT at admission did not correlate with median ADAMTS13 
or VWF levels.  
 
This is in agreement with a study by Basuki et al in from Indonesia on 41 children with 
DF / DHF  that showed that although elevated VWF levels with decreased platelets was 
seen early in dengue, changes in platelet count and VWF correlated poorly with course of 
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dengue illness (42). The study by Djamiatun et al in Indonesian children with dengue 
found only non-significant differences in clinical characteristics between DHF and DSS 
patients. They too failed to demonstrate any significant correlation between VWF-related 
factors and markers of dengue severity such as platelets, SGOT and albumin levels in 
their children (7). Chuansumrit et al took daily blood samples from  children with dengue 
in Thailand and found that platelet counts were lowest in children with DSS (dengue 
shock syndrome) compared to those with DHF (dengue hemorrhagic fever), which were 
in turn lower than those with DF (dengue fever). However, levels of VWF were not 
significantly higher between DF and DHF, with only those with DSS showing higher 
VWF activity. They also documented return of all parameters including VWF to normal 
2-4 weeks after discharge from hospital (41).  
 
A study from Pakistan documented low ADAMTS13 levels in 65% of 80 pediatric 
patients with severe sepsis, and showed that mortality was higher at 42.3% in 
ADAMTS13-deficient children compared to 35.7% mortality in non-deficient children 
(43). Both the children who died within our cohort of 132 had severe dengue. Their VWF 
and ADAMTS13 were not different from those who survived. The study by Djamiatun et 
al showed no difference in ADAMTS13 levels or VWF antigen or VWF propeptide 
factor in 6 children with DSS who died compared to those who survived, although VWF 
activation factor was two-fold higher in those who died (7).  
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In summary, it is evident from the results of our small study that markers of endothelial 
injury such as low ADAMTS13 activity and elevated VWF activity are present in all 
stages and phases of dengue infection in children from India.  The median levels of 
ADAMTS13 and VWF activity did not correlate with either the WHO stages of the 
disease or the phases of the illness, and therefore cannot be used as prognostic 
biomarkers of severity of illness due to dengue. Although our study subjects may not be 
directly comparable due to the earlier WHO staging system used in other studies, it is 
also evident that clinical and laboratory markers of severity of illness do not perfectly 
correlate with levels of VWF and ADAMTS13, as has already been evidenced in those 
studies. Further studies are necessary for defining normal levels of ADAMTS13 and 
VWF in normal children from India as well as to see which interventions are best in these 
situations(44), such as fibrinolytic therapy(45), plasma exchange or use of 
cryosupernatant rich in ADAMTS13 (46)  to reduce the impact of endothelial injury in 
children with dengue infection.                
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CONCLUSIONS 
 
 
1. ADAMTS13 levels were deficient in 96% of study children, irrespective of stage 
or phase of dengue infection. 
2. Severe ADAMTS13 deficiency was documented in 82.5% of study children. 
3. ADAMTS13 activity was reduced in both the febrile phase and early toxic phase 
of illness in children with dengue.  
4. There was a statistically significant difference in ADAMTS13 levels between 
dengue stages according to the 2012 WHO classification, as well as between 
severe and non-severe dengue. ADAMTS13 levels were likely to be lower in 
children with non-severe dengue compared to severe dengue. 
5. Von Willebrand Factor (VWF) activity by collagen-binding assay (CBA) was 
elevated in 89% of children with dengue infection.  
6. VWF activity was elevated in severe dengue compared to non-severe dengue, and 
in the early toxic phase (day 5 +) compared to the febrile phase (days 1-4) in 
children with severe dengue.   
7. Neither ADAMTS13 nor VWF activity levels were predictive of the WHO clinical 
stage of severity of dengue infection in our children. 
8. Hepatomegaly, ascites and pleural effusion, bleeding manifestations, need for 
blood product and inotropic support and total duration of hospital stay were all 
significantly higher in children with severe dengue. 
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9. Hepatomegaly at admission and need for ICU admission were seen in children 
with higher median VWF levels. 
10. Need for blood support was significantly associated with lower ADAMTS13 
levels. 
11. Other clinical and laboratory markers of severity of illness did not correlate with 
VWF or ADAMTS13 levels in children with dengue. 
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LIMITATIONS 
 
1. The majority of our children had dengue with warning signs, with a lesser number 
of children with severe dengue and only a very few with dengue alone. This may 
have contributed to our inability to show a significant difference in ADAMTS13 
and VWF levels between groups. 
2.  The absence of a control group of normal children from the same geographic 
location may also have contributed to the lack of difference in ADAMTS13 and 
VWF levels between groups. 
3. The fact that most children presented between 3 to 5 days of the illness prevented 
us from documenting differences in ADAMTS13 and VWF activity in the earliest 
days of dengue infection.  
4. ADAMTS13 and VWF activity was measured at a single point in time, i.e. 
presentation to hospital. Although this fulfilled our primary objective, this 
prevented us from documenting changes in ADAMTS13 and VWF with therapy 
and during the recovery phase of dengue illness. 
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ANNEXURES  
Proforma  
ADAMTS13 and VWF levels as prognostic markers in dengue 
Study No  Date  
Name  
Age; DOB  
Sex  
Weight  
Address  
Cell no  
Final diagnosis Dengue fever 
without warning 
signs 
Dengue fever with 
warning signs (Fever 
+ 2 of: nausea / 
vomiting; rash; aches 
and pains; positive 
tourniquet test; 
leucopenia) 
Severe dengue 
(DSS / respiratory 
distress / severe 
bleeding / ALT > 
1000 / Impaired 
consciousness / heart 
/ other organ (circle 
all that apply) 
Final outcome at 
discharge: 
 
Alive / Dead / 
Discharged in 
moribund state / 
against medical 
advice 
Findings at admission 
 Present Absent 
Date of fever onset   
Fever duration (days)   
Nausea / vomiting   
Rash   
Aches and pains   
Positive tourniquet test   
Leukopenia   
Warning signs:   
Abdominal pain / 
tenderness 
  
Persistent vomiting   
Ascites / Pleural effusion   
Mucosal bleed   
Lethargy / restlessness   
Liver > 2 cm   
Increase HCT + fall 
platelets 
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Dengue IgM done on (date) 
 At admission Day 1 Day 2 Day 3 Day 4 
Temperature      
Hb      
Platelets      
PT      
PTT      
Pleural effusion 
(clinical / Weil‟s 
sign): Y/N 
     
Hepatomegaly 
Y/N 
     
Ascites Y/N      
Bleeding 
manifestations Y/N 
     
Shock 
Y/N 
     
Inotropes 
Y/N 
     
Transfusions 
Y/N 
     
 
 Day 5 Day 6 Day 7 Day 8 Day 9 
Temperature      
Hb      
Platelets      
PT      
PTT      
Pleural  effusion 
(clinical / Weil‟s 
sign): Y/N 
     
Hepatomegaly 
Y/N 
     
Ascites Y/N      
Bleeding 
manifestations 
Y/N 
     
Shock 
Y/N 
     
Inotropes 
Y/N 
     
Transfusions 
Y/N 
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Consent form 
 
 CONSENT TO TAKE PART IN THE STUDY  
Study Title : ADAMTS13 and VWF levels as prognostic markers in dengue  
Study Number:  
Participant’s name:  
Date of Birth / Age (in years):  
I_____________________________________________________________  
father/mother/guardian of ______________________________________  
(Please tick boxes)  
Declare that I have read the information sheet provided to me regarding this study and 
have clarified any doubts that I had. [ ]  
I also understand that my child‟s participation in this study is entirely voluntary and that I  
am free to withdraw permission to continue to participate at any time without affecting 
my  
child‟s usual treatment or his/her legal rights [ ]  
I also understand that during the study, I will pay for routine care of my child‟s illness, 
including blood tests that are deemed necessary by the treating doctors. [ ]  
I understand that the study staff and institutional ethics committee members will not need  
my permission to look at my child‟s health records both with respect to the current study 
and any further research that may be conducted in relation to it, even if I withdraw from 
the study. I agree to this access. [ ]  
I understand that my child‟s identity will not be revealed in any information released to  
third parties or published. [ ]  
I voluntarily agree to take part in this study [ ]  
Name: __________________________________________ Date:  
Relation to participant:_____________________________  
Signature / Thumb impression:  
Name of witness:__________________________________ Date:  
Signature / Thumb impression:  
Study Investigator‟s Name: _________________________  
Signature of the Investigator: ________________________  
Date: 
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Information sheet  
 
Christian Medical College, Vellore 
Department of Paediatrics 
ADAMTS13 and VWF levels as prognostic markers in dengue 
Information 
sheet 
You are being requested to participate in a study to estimate the level of serum 
ADAMTS13 and von 
Willebrand Factor (VWF) along with other routine blood investigations to 
identify the disease course of dengue. 
What is Dengue? 
Dengue is one of the the most important mosquito-borne viral disease. It is also known 
as  breakbone fever. There are four different viruses that can cause dengue fever, all 
of which spread by a certain type of mosquito. It causes a severe flu-like illness. 
Dengue fever can vary from mild to severe; the more severe forms include dengue 
shock syndrome and dengue hemorrhagic fever (DHF). Patients who develop the more 
serious forms of dengue fever usually need to be hospitalized.  Its treatment is mainly 
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supportive. The best way to prevent the disease is to avoid being bitten by mosquitoes 
altogether. 
 
What are ADAMTS13 and von Willebrand Factor(VWF)? Why it is important to 
estimate the level?  
Von Willebrand factor (vWF) is type of protein present in our blood which is involved 
in clotting 
mechanism.  It normally helps in clotting of blood. 
ADAMTS13 is an enzyme that breaks von Willebrand factor (vWf), thereby decreasing 
its activity and inhibits clotting process. Thus for a normal function of blood system 
both the levels should be kept with appropriate levels. Following dengue infection there 
is an inhibition of ADAMTS 13 due to various reasons, thus altering both these levels. 
Western studies have shown that decrease in ADAMTS13 and increase in von 
Willebrand Factor (VWF) are associated with the severe forms of dengue. If we prove 
that the same happens in Indian children with dengue, it can be used to predict 
progression of mild disease to severe forms of dengue. 
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If you take part in this study, what will you have to do? 
If you agree to participate in this study, your child will be enrolled and followed up 
throughout the hospital stay. In addition to routine blood testing required by your 
treating doctors, one sample of blood will be stored for testing for levels of ADAMTS 
13 and von Willebrand factor (vWf), which will be done if your child is proved to have 
dengue infection. All the tests are performed with a simple venipuncture procedure 
which is very minimally invasive.  There are no adverse effects for this routine 
procedure. Once the blood sample is taken, your child can continue treatment as per the 
hospital‟s protocol for treatment of dengue 
Can you withdraw from this study? 
Your participation in this study is entirely voluntary and you are also free to 
decide to withdraw permission to participate in this study. If you do so, this will 
not affect your child‟s usual treatment at this hospital in any way. 
What will happen if you develop any study related injury? 
Our study is to estimate the levels of ADAMTS13 and von Willebrand Factor (VWF) 
along with the mandatory test required for your child. The tests will be performed by 
simple venipucture. Hence study related injury is very unlikely. 
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Will you have to pay for the treatment and investigations? 
You need not pay for analysis of the levels of ADAMTS13 and von Willebrand Factor 
(VWF). 
You have to pay for the routine tests performed during your child‟s treatment for 
dengue, including Complete blood count (CBC), PT,PTT, SGPT & Dengue serology. 
What happens after the study is over? 
The tests for ADAMTS13 and von Willebrand Factor (VWF) may be available only 
after your child‟s treatment is completed, so the results will not be useful for the 
doctors treating your child. However, if the results of this study prove that these tests 
are useful to predict the severity of dengue, this may help make this a routine test for 
dengue and indirectly benefit future generations of children suffering from dengue. 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not 
be identified by name in any publication or presentation of results. However, 
your medical notes may be reviewed by people associated with the study, 
without your additional permission. 
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If you have any further questions, 
please contact : Dr. Sivamurukan, Department of Paediatrics, CMC, Vellore 
Tel:  0416 2283343 
Mobile: 967737789  
Email: sivamurukan@gmail.com  
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